If You Invested in Scinai Immunotherapeutics Ltd. (SCNI)

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company active in the development and manufacturing of biological products for inflammation and immunology (I&I) indications. According to the company’s public disclosures, Scinai operates through two complementary business units: an internal R&D organization focused on I&I biological therapeutics, and a boutique contract development and manufacturing organization (CDMO) serving biotech clients worldwide.

The company is classified in the biological product manufacturing space within the broader manufacturing sector. Its stock trades on Nasdaq under the ticker SCNI. Scinai’s operations and SEC filings describe a business model that combines proprietary drug development with fee-for-service development and manufacturing activities for third parties.

Business Structure and Core Activities

Scinai’s disclosures describe two business units:

• Scinai Bioservices (CDMO) – a boutique CDMO that provides biological drug development, analytical method development, process development, and clinical cGMP manufacturing services for biotech clients. Press releases note that this unit supports early-stage biotech companies in Israel, the United States, and Europe, including through a U.S. subsidiary. Activities include small-batch sterile fill-and-finish capabilities and support from early clone selection through drug substance and drug product manufacturing for pre-clinical and clinical studies.
• Scinai R&D – an internal research and development unit focused on inflammation and immunology (I&I) biological therapeutics. Company communications describe an “innovative, de-risked pipeline” of nanosized VHH antibodies (NanoAbs), also referred to as VHH antibody fragments, targeting diseases with large unmet medical needs. These NanoAbs are described as having unique physicochemical properties suitable for advanced mono- and multi-specific antibody formats.

Multiple press releases state that Scinai generates revenue primarily from its CDMO activities, with CDMO revenues reported as the main contributor to the company’s top line once that business began operating.

Inflammation and Immunology (I&I) Pipeline

Scinai’s R&D unit focuses on I&I programs built around NanoAbs and other biological candidates. Based on company news, key elements include:

• Anti-IL-17 NanoAb programs – Scinai reports development of NanoAb-based products targeting IL‑17A and IL‑17F for dermatological and broader I&I indications. Disclosures describe:
  • An intradermal IL‑17A/F NanoAb candidate (referred to as SCN‑1 in company news) for localized treatment of plaque psoriasis, designed as a first localized biologic for mild–moderate psoriasis. The company describes intradermal delivery using a mesogun to enable targeted treatment with limited systemic exposure and a positioning between topical therapies and systemic biologics.
  • A bispecific IL‑17A/F plus second target VHH‑Fc biologic intended as a long-acting systemic therapy for psoriasis, psoriatic arthritis, hidradenitis suppurativa, and other I&I indications. Company materials describe a dual-target VHH‑Fc architecture designed for enhanced biologic activity and extended half-life.
• Collaboration with Max Planck Society and University Medical Center Göttingen – Scinai reports a research collaboration that has generated four additional NanoAbs in I&I. The company states that patent applications for these NanoAbs were filed and that it holds or plans to exercise exclusive options to in-license them, expanding its pipeline into additional I&I pathways.
• PC111 program via Pincell option – Scinai has a binding option agreement to acquire Pincell Srl, an Italian biotech company developing PC111, described as a first-in-class human anti-Fas Ligand monoclonal antibody. Company news states that PC111 targets the soluble form of Fas Ligand (sFasL) and is being developed for severe dermatological conditions such as pemphigus vulgaris and Stevens‑Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). Scinai reports that PC111 has received orphan drug designation in pemphigus in the European Union and that peer‑reviewed publications support its disease‑modifying potential in preclinical models.

Scinai’s communications emphasize that its I&I programs are intended to address areas of high unmet need and that it is actively exploring co-development, licensing, and platform partnerships across its pipeline.

CDMO Services and Biopharma Manufacturing Role

Through Scinai Bioservices, the company positions itself as a boutique CDMO with a focus on early-stage biotech clients. Public statements describe:

• Analytical method development and process development capabilities for biologics.
• Clinical cGMP manufacturing services, including drug substance and drug product manufacturing for pre-clinical and clinical studies.
• Sterile fill-and-finish capabilities for small batches, supported by a grant from the Israel Innovation Authority (IIA) to fund an advanced fill‑and‑finish system.
• Support for clients in Israel, the U.S., and Europe, with company disclosures noting that a U.S. subsidiary contributes to CDMO revenues.

In its news releases, Scinai notes that Israel’s biopharma sector has a shortage of flexible, small-scale GMP manufacturing infrastructure and that Scinai Bioservices is contributing to address this gap. The IIA’s grant decision is cited by the company as recognizing the importance of CDMO services for early-stage pharmaceutical and academic teams that need access to advanced facilities and expertise.

Financing, Grants, and Strategic Partnerships

Scinai’s SEC filings and press releases describe several financing and partnership-related elements:

• Standby Equity Purchase Agreements (SEPA) with Yorkville Advisors, allowing the company to raise capital through the sale of American Depositary Shares (ADSs) over a defined period, subject to conditions and caps. A 6‑K filing details a SEPA with a commitment amount of up to $15 million and outlines pricing and ownership limits.
• Non-dilutive grant funding – Scinai reports a grant from the Israel Innovation Authority to support acquisition and installation of an advanced sterile fill‑and‑finish system for its CDMO unit. It also describes applications for EU STEP grants for its IL‑17 programs and a FENG grant in Poland for the PC111 program, although one FENG application for PC111 was later reported as not selected for funding, with an appeal process described in a 6‑K.
• Option to acquire Pincell Srl – The company has a binding option to acquire 100% of Pincell’s share capital, subject to conditions including funding for PC111’s development. A press release notes that Scinai received Italian government clearance under the Golden Power regulation for this potential acquisition, removing a key regulatory condition.

Corporate Governance and Regulatory Filings

As a foreign private issuer, Scinai files annual reports on Form 20‑F and interim updates on Form 6‑K with the U.S. Securities and Exchange Commission. Recent 6‑K filings include:

• Notices regarding annual general meetings of shareholders and related proxy materials.
• Information on changes in the board of directors and changes in the independent registered public accounting firm, described as part of cost-cutting measures.
• Incorporation by reference of press releases reporting financial results, business updates, and grant awards.

These filings provide investors with updates on Scinai’s financial performance, capital structure, governance, and material business developments.

Position Within the Biopharmaceutical Ecosystem

Based on its own descriptions, Scinai occupies a dual role in the biopharmaceutical ecosystem:

• As a drug developer, it focuses on I&I biologics, including NanoAb-based therapies and PC111, aiming at dermatological and systemic immune-mediated diseases.
• As a service provider, it operates a boutique CDMO that offers development and manufacturing services tailored to early-stage biotech projects, with an emphasis on flexibility, small-batch capabilities, and close scientific collaboration.

This combination of internal pipeline and external service revenues is a central theme in the company’s communications and SEC disclosures.